ArteriopathySOFtPERIPHERALNCT03546881
Safety of Fusion Guidance During Peripheral Revascularisation
A study testing fusion imaging guidance technology and 2D X-ray screen in people with Arteriopathy, run by Nantes University Hospital at 1 site in France.
Trial summary
Study the Patient and staff Safety regarding the radiation exposure during the procedure with and without the fusion imaging guidance technology in treatment of peripheral artery disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arteriopathy
- What is being tested?
- fusion imaging guidance technology and 2D X-ray screen
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 77 participants
- Where
- 1 siteFrance
- Study dates
- 18 Jun 2018to 16 Oct 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to give informed consent
- Male or Female
- Aged 18 or older
- Have been scheduled for peripheral endovascular revascularisation of an occlusive arterial disease excluding isolated infra popliteal revascularisation
- Who have had a pre-operative diagnostic CT scan
- Able (in the investigator's opinion) and willing to comply with the study requirements
- Covered by the French public health insurance system
Who cannot join
- Female under the age of 50 years old.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Any patient requiring an associated procedure: renal or mesenteric angioplasty.
- Adult under guardianship or trusteeship
Trial locations and contacts
1 site in 1 country.
France1 site
Nantes University Hospital, Vascular surgery, Institut du Thorax
Nantes, 44093
About this study
Official title: A Prospective Single Center Randomized Interventional Controlled Open Trial Comparing Patient and Staff Safety During Peripheral Endovascular Arterial Revascularisation Using Advanced Imaging Guidance Technology to Control Group Without Imaging Guidance.
Study the Patient and staff Safety regarding the radiation exposure during the procedure with and without the fusion imaging guidance technology in treatment of peripheral artery disease.
Read the detailed description
The investigators are proposing a prospective, monocentric trial to assess the use of fusion imaging in peripheral endovascular revascularisation. The main aim of this research is to prove that using fusion imaging guidance during peripheral endovascular revascularisation improve the patient and staff safety in the theatre, through a reduction of radiation exposure.
Peripheral artery occlusive disease (PAOD) is a worldwide well known disease, with atherosclerosis as a leading cause. One third of patients with PAOD are symptomatic, typically presenting with claudication, and in a very much less proportion with critical limb ischemia. These last patients are high risk for major limb amputation without revascularisation. Once symptomatic PAOD diagnosed, a CT-scan is required to assess the anatomy and if indicated an endovascular revascularisation of the lower limbs arteries is performed. This minimally invasive procedure allows the improvement of the hemodynamic flow into the lower limb, by positioning one or several stents inside the diseased arteries through a femoral or an humeral access under live X-rays (fluoroscopy) guidance.
X-rays are good at showing bones and radio-opaque endovascular tools, but they do not show soft tissues like the arteries, and they produce flat (2D) images that superimpose all the 3D anatomical features. In order to see the arteries, physicians have to inject iodinated contrast during high quality imaging recording, which can be toxic for the kidneys, and increases the amount of radiation used. Consequently, the drawbacks of this mini-invasive procedure are the X-rays radiation exposure for both patients and medical staff, and the need of iodinated contrast injection that can lead to lifelong kidney problems. Reducing both in order to decrease their respective toxicities must be a priority for the endovascular therapist. Several studies including guidelines recall basic safety standards for protection against X-rays and iodinated contrast exposure.
One way to reduce both radiation and contrast use is to improve clinicians' perception of intraoperative 3D vascular anatomy. Advanced imaging techniques allow overlay of a 3D version of the aorta from a pre-operative CT scan (a 3D vascular mask) onto the live X-ray image creating a '3D roadmap' - a virtual reality that helps guide surgery. It has been proven that using fusion imaging guidance during aortic endovascular repair reduce both contrast and radiation dose, especially if the registration protocol is contrast and almost radiation free. The investigators have recently completed research showing that they are able to use an advanced imaging application to dramatically reduce our radiation dose for complex aneurysms.
Traditionally, this advanced imaging application is currently available only in modern expensive hybrid theatres, and not used in everyday practice during peripheral endovascular revascularisation procedures. However new technologies are about to supply similar imaging to any interventional equipment, which will change the way endovascular procedures are performed worldwide. That's why using fusion imaging guidance routinely as a standard of care may be part of good practice to improve patient and staff safety. However, to our knowledge, the impact of using fusion on radiation dose and contrast use has not been validated for peripheral endovascular procedures.
This trial will examine the clinical benefits of using fusion imaging guidance during peripheral endovascular revascularisation procedures based on the radiation exposure, as compared with procedures without imaging guidance. The design of the study is to compare a prospective single centre cohort of 88 consecutive patients scheduled for an endovascular peripheral procedure and randomised either as using the imaging guidance overlay, or to a control cohort of patients whose procedure will be performed without imaging guidance (standard of care).
This study is a Low risk and constraints study, because it's a standard care procedure with no additional risks.
- Conditions
- Arteriopathy
- Being tested
- fusion imaging guidance technology, 2D X-ray screen
- Keywords
- PAOD, endovascular, fusion, radiation, exposure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
fusion imaging guidance technologyProcedure or surgery
Imaging fusion guidance overlay used during PAOD endovascular revascularisation
2D X-ray screenProcedure or surgery
2D X-ray screen during PAOD endovascular revascularisation
| Study group | Role | What they receive |
|---|---|---|
| Arm with fusion imaging guidance technology | Experimental | arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system. Receives: Procedure: fusion imaging guidance technology; Procedure: 2D X-ray screen |
| Arm without fusion imaging guidance technology | Active comparator | arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery. Receives: Procedure: 2D X-ray screen |
What is being measured
The primary outcome is the main question the study is designed to answer.
DAP (Dose Aera Product in Gy.cm²) by the end of the procedure,
The DAP is a surrogate measurement for the entire amount of energy delivered to the patient by the beam.
Measured: day 0, per procedure
Secondary outcomes (6)
AK (Air Kerma, in Gy)
an indirect measurement automatically reported by the fluoroscopy equipment thus highly reproducible and responsive to change in X-rays emission
Measured: day 0, per procedure
Number of DSA (Digital Subtraction Angiography) runs
runs (Digital subtraction angiography) along the procedure. The DSA allows high quality loop acquisition with subtraction of non-vascular structures that requires substantial additional radiation exposure compared with standard fluoroscopy
Measured: day 0, per procedure
FT (Fluoroscopy Time, min).
a counting of the time spent using fluoroscopy.
Measured: day 0, per procedure
Radiation exposure to the operator (Sv).
The operator's exposure to radiation, recorded by a live dosimeter
Measured: day 0, per procedure
Iodinated contrast volume (ml).
repeated injections of contrast media contribute to the development of lifelong nephropathy, predominantly in patients with diabetic nephropathy (19.7%) and pre-existing renal impairment (3%-33%)
Measured: day 0, per procedure
Total operative time ( min)
time of the operation, between the first puncture and the end of the procedure
Measured: day 0, per procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2018
- Study start18 Jun 2018
- Primary completion16 Oct 2019
- Study completion16 Oct 2019
Why it stopped: Premature termination of the research following an internal reorganization of the team no longer allowing the necessary resources to continue the study
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ArteriopathyStudies of the same condition, open and under way.
- More trials run by Nantes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nantes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Blandine Maurel, MD, Principal investigator, Nantes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03546881
- Sponsor's protocol ID
- RC17_0473
- Acronym
- SOFtPERIPHERAL
- Status last verified
- May 2023
- First submitted
- 23 May 2018
- Last updated
- 23 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single Center Randomized Interventional Controlled Open Trial Comparing Patient and Staff Safety During Peripheral Endovascular Arterial Revascularisation Using Advanced Imaging Guidance Technology to Control Group Without Imaging Guidance.
- ClinicalTrials.gov ID
- NCT03546881
- Acronym / sponsor ID
- SOFtPERIPHERAL / RC17_0473
- Conditions
- Arteriopathy
- Keywords
- PAOD, endovascular, fusion, radiation, exposure
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Premature termination of the research following an internal reorganization of the team no longer allowing the necessary resources to continue the study
- Enrolment
- 77 participants (actual)
- Lead sponsor
- Nantes University HospitalUniversity, hospital or other
- Study start
- 18 Jun 2018 (actual)
- Primary completion
- 16 Oct 2019 (actual)
- Study completion
- 16 Oct 2019 (actual)
- First posted
- 6 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study the Patient and staff Safety regarding the radiation exposure during the procedure with and without the fusion imaging guidance technology in treatment of peripheral artery disease.
Detailed description
The investigators are proposing a prospective, monocentric trial to assess the use of fusion imaging in peripheral endovascular revascularisation. The main aim of this research is to prove that using fusion imaging guidance during peripheral endovascular revascularisation improve the patient and staff safety in the theatre, through a reduction of radiation exposure.
Peripheral artery occlusive disease (PAOD) is a worldwide well known disease, with atherosclerosis as a leading cause. One third of patients with PAOD are symptomatic, typically presenting with claudication, and in a very much less proportion with critical limb ischemia. These last patients are high risk for major limb amputation without revascularisation. Once symptomatic PAOD diagnosed, a CT-scan is required to assess the anatomy and if indicated an endovascular revascularisation of the lower limbs arteries is performed. This minimally invasive procedure allows the improvement of the hemodynamic flow into the lower limb, by positioning one or several stents inside the diseased arteries through a femoral or an humeral access under live X-rays (fluoroscopy) guidance.
X-rays are good at showing bones and radio-opaque endovascular tools, but they do not show soft tissues like the arteries, and they produce flat (2D) images that superimpose all the 3D anatomical features. In order to see the arteries, physicians have to inject iodinated contrast during high quality imaging recording, which can be toxic for the kidneys, and increases the amount of radiation used. Consequently, the drawbacks of this mini-invasive procedure are the X-rays radiation exposure for both patients and medical staff, and the need of iodinated contrast injection that can lead to lifelong kidney problems. Reducing both in order to decrease their respective toxicities must be a priority for the endovascular therapist. Several studies including guidelines recall basic safety standards for protection against X-rays and iodinated contrast exposure.
One way to reduce both radiation and contrast use is to improve clinicians' perception of intraoperative 3D vascular anatomy. Advanced imaging techniques allow overlay of a 3D version of the aorta from a pre-operative CT scan (a 3D vascular mask) onto the live X-ray image creating a '3D roadmap' - a virtual reality that helps guide surgery. It has been proven that using fusion imaging guidance during aortic endovascular repair reduce both contrast and radiation dose, especially if the registration protocol is contrast and almost radiation free. The investigators have recently completed research showing that they are able to use an advanced imaging application to dramatically reduce our radiation dose for complex aneurysms.
Traditionally, this advanced imaging application is currently available only in modern expensive hybrid theatres, and not used in everyday practice during peripheral endovascular revascularisation procedures. However new technologies are about to supply similar imaging to any interventional equipment, which will change the way endovascular procedures are performed worldwide. That's why using fusion imaging guidance routinely as a standard of care may be part of good practice to improve patient and staff safety. However, to our knowledge, the impact of using fusion on radiation dose and contrast use has not been validated for peripheral endovascular procedures.
This trial will examine the clinical benefits of using fusion imaging guidance during peripheral endovascular revascularisation procedures based on the radiation exposure, as compared with procedures without imaging guidance. The design of the study is to compare a prospective single centre cohort of 88 consecutive patients scheduled for an endovascular peripheral procedure and randomised either as using the imaging guidance overlay, or to a control cohort of patients whose procedure will be performed without imaging guidance (standard of care).
This study is a Low risk and constraints study, because it's a standard care procedure with no additional risks.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm with fusion imaging guidance technology | Experimental | Procedure: fusion imaging guidance technology, Procedure: 2D X-ray screenarm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system. |
| Arm without fusion imaging guidance technology | Active comparator | Procedure: 2D X-ray screenarm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Willing and able to give informed consent
- Male or Female
- Aged 18 or older
- Have been scheduled for peripheral endovascular revascularisation of an occlusive arterial disease excluding isolated infra popliteal revascularisation
- Who have had a pre-operative diagnostic CT scan
Key exclusion criteria (4 listed)
- Female under the age of 50 years old.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Any patient requiring an associated procedure: renal or mesenteric angioplasty.
- Adult under guardianship or trusteeship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| fusion imaging guidance technologyImaging fusion guidance overlay used during PAOD endovascular revascularisation | Procedure or surgery | Arm with fusion imaging guidance technology |
| 2D X-ray screen2D X-ray screen during PAOD endovascular revascularisation | Procedure or surgery | Arm with fusion imaging guidance technology, Arm without fusion imaging guidance technology |
Primary outcome
DAP (Dose Aera Product in Gy.cm²) by the end of the procedure,
Time frame: day 0, per procedure
The DAP is a surrogate measurement for the entire amount of energy delivered to the patient by the beam.
6 secondary outcomes
AK (Air Kerma, in Gy)
Time frame: day 0, per procedure
Number of DSA (Digital Subtraction Angiography) runs
Time frame: day 0, per procedure
FT (Fluoroscopy Time, min).
Time frame: day 0, per procedure
Radiation exposure to the operator (Sv).
Time frame: day 0, per procedure
Iodinated contrast volume (ml).
Time frame: day 0, per procedure
Total operative time ( min)
Time frame: day 0, per procedure
Results and safety
The study was stopped early (reason given: Premature termination of the research following an internal reorganization of the team no longer allowing the necessary resources to continue the study). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2023.
Related trials for Arteriopathy
RecruitingPhase 1/2
Retina is a Marker for Cerebrovascular Heath
Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
Not yet recruiting
Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2
CADASIL, Cavernous Angioma
Enrolling by invitationPhase 4
Focal Cerebral Arteriopathy Steroid Trial
Pediatric Stroke, Arteriopathy
RecruitingObservational study
Measurement of Brain Perfusion by a MR Perfusion Imaging Called eASL in Children's Cerebral Arteriopathies.
Cerebral Arteriopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Blandine Maurel, MD principal investigator
Nantes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing fusion imaging guidance technology and 2D X-ray screen in people with Arteriopathy, run by Nantes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Premature termination of the research following an internal reorganization of the team no longer allowing the necessary resources to continue the study). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DAP (Dose Aera Product in Gy.cm²) by the end of the procedure, (time frame: day 0, per procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2023; AzTrials last refreshed its copy on 7 Nov 2026.